Free Trial
NASDAQ:TXMD

TherapeuticsMD (TXMD) Stock Price, News & Analysis

TherapeuticsMD logo
$1.46 -0.06 (-3.95%)
As of 04:00 PM Eastern

About TherapeuticsMD Stock (NASDAQ:TXMD)

Key Stats

Today's Range
$1.46
$1.54
50-Day Range
$0.73
$1.52
52-Week Range
$0.70
$2.44
Volume
23,142 shs
Average Volume
155,286 shs
Market Capitalization
$16.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

TherapeuticsMD Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
28th Percentile Overall Score

TXMD MarketRank™: 

TherapeuticsMD scored higher than 28% of companies evaluated by MarketBeat, and ranked 776th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for TherapeuticsMD.

  • Price to Book Value per Share Ratio

    TherapeuticsMD has a P/B Ratio of 0.53. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    1.29% of the float of TherapeuticsMD has been sold short.
  • Short Interest Ratio / Days to Cover

    TherapeuticsMD has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in TherapeuticsMD has recently decreased by 13.42%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    TherapeuticsMD does not currently pay a dividend.

  • Dividend Growth

    TherapeuticsMD does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.29% of the float of TherapeuticsMD has been sold short.
  • Short Interest Ratio / Days to Cover

    TherapeuticsMD has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in TherapeuticsMD has recently decreased by 13.42%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    TherapeuticsMD has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for TherapeuticsMD this week, compared to 0 articles on an average week.
  • Search Interest

    3 people have searched for TXMD on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, TherapeuticsMD insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,803.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 2.30% of the stock of TherapeuticsMD is held by insiders.

  • Percentage Held by Institutions

    Only 30.74% of the stock of TherapeuticsMD is held by institutions.

  • Read more about TherapeuticsMD's insider trading history.
Receive TXMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TherapeuticsMD and its competitors with MarketBeat's FREE daily newsletter.

TXMD Stock News Headlines

Silver Demand Is Soaring-Supply Can't Keep Up
Silver demand hit 1.16 billion ounces in 2024-while supply fell short again for the fourth year in a row. Industrial demand is rising fast, but new supply isn't keeping pace. For investors, that opens the door to one key question: who already has it? One project in N. America just reported high-grade results at a time when ounces in the ground are becoming harder to find-and more valuable.
See More Headlines

TXMD Stock Analysis - Frequently Asked Questions

TherapeuticsMD's stock was trading at $0.86 on January 1st, 2025. Since then, TXMD shares have increased by 69.8% and is now trading at $1.46.
View the best growth stocks for 2025 here
.

TherapeuticsMD, Inc. (NASDAQ:TXMD) released its earnings results on Tuesday, May, 13th. The company reported ($0.06) earnings per share (EPS) for the quarter. The business had revenue of $0.39 million for the quarter. TherapeuticsMD had a negative net margin of 207.77% and a negative trailing twelve-month return on equity of 14.08%.

TherapeuticsMD shares reverse split on the morning of Monday, May 9th 2022. The 1-50 reverse split was announced on Monday, May 9th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

TherapeuticsMD's top institutional investors include Tejara Capital Ltd (2.98%) and Simplex Trading LLC. Insiders that own company stock include Rubric Capital Management Lp, Marlan D Walker, Cooper C Collins, Michael C Donegan, Brian Bernick and Gail K Naughton.
View institutional ownership trends
.

Shares of TXMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that TherapeuticsMD investors own include Voyager Therapeutics (VYGR), Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Marinus Pharmaceuticals (MRNS), AUO (AUOTY) and The RMR Group (RMR).

Company Calendar

Last Earnings
5/13/2025
Today
5/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TXMD
Previous Symbol
NYSEMKT:TXMD
Employees
420
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-10,280,000.00
Net Margins
-207.77%
Pretax Margin
-251.25%

Debt

Sales & Book Value

Annual Sales
$1.76 million
Price / Cash Flow
N/A
Book Value
$2.77 per share
Price / Book
0.54

Miscellaneous

Free Float
11,267,000
Market Cap
$17.25 million
Optionable
Optionable
Beta
0.50

Social Links

20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (NASDAQ:TXMD) was last updated on 5/14/2025 by MarketBeat.com Staff
From Our Partners